Genomic DNA in CD34+ hematopoietic stem cell (None)

Genomic DNA in CD34+ hematopoietic stem cells refers to the entirety of hereditary genetic material contained within these rare, multipotent cells, which reside primarily in the bone marrow, peripheral blood, and umbilical cord blood. CD34+ HSCs are the earliest cellular precursors of all blood cell types, and their genomic DNA encodes the full range of genes necessary for hematopoiesis, self-renewal, and differentiation. While the genomic DNA itself is not a direct therapeutic target, mutations or structural alterations within this DNA compartment underlie a variety of blood disorders, including leukemia, myelodysplastic syndromes, and bone marrow failure states. For research and clinical applications, gene expression profiling, genome editing (e.g., CRISPR-Cas9), and mutational analysis of the genomic DNA in CD34+ HSCs provide insights into stem cell biology and serve as foundations for cellular engineering and gene therapy approaches, but "genomic DNA" as a whole is not a classical molecular or drug target.

Other names

Genomic DNA of CD34+ hematopoietic stem cellsGenomic DNA (CD34+ HSC)Whole genome (CD34+ cell)

Not applicable (genomic DNA is not directly druggable; gene editing technologies such as CRISPR-Cas9 can modify DNA sequences within CD34+ cells, but the mechanism is mediated by the editing tools, not the DNA itself)